Las Vegas, NV -- (SBWIRE) -- 12/18/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Tower Group International, Ltd. (NASDAQ:TWGP), American Superconductor Corporation (NASDAQ:AMSC), Hemispherx BioPharma, Inc(NYSEMKT:HEB), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Tower Group International, Ltd. (NASDAQ:TWGP) managed to keep its fall at -2.72% on below -normal volume of 2.14M shares. The stock settled at $3.93 after floating in a range of $3.83 to $4.09. Its latest price has reached market capitalization of $232.03 million. Its 52-week range has been $3.53 to $22.30. Tower Group International, Ltd., through its subsidiaries, underwrites insurance and reinsurance products in Bermuda, the United States, and London markets. The company provides commercial, personal, and specialty insurance and reinsurance products.
Has TWGP Found The Bottom and Ready To Move Up? Find Out Here
American Superconductor Corporation (NASDAQ:AMSC) traded up on a volume of 2.11 million, higher than its standard daily volume. Shares have gained 3.60% to $1.44. Over the last twelve months, the stock has lost-52.94% and faced a worst price of $1.37. American Superconductor Corporation (AMSC) is a provider of megawatt-scale solutions that lower the cost of wind power and enhance the performance of the power grid. It operates in two business units: Wind and Grid. Wind business segment enables manufacturers to field wind turbines with power output, reliability and affordability. Grid business segment enables electric utilities and renewable energy project developers to connect, transmit and distribute power with efficiency, reliability and affordability.
For How Long AMSC s Gloss will Attract Investors? Find out via this report
Hemispherx BioPharma, Inc(NYSEMKT:HEB) settled 0.26% higher at $0.271 on above-normal volume of 2.09M shares during the last trading day. The stock has its 12-month high at $0.71 and 52-week low price was $0.18. It traded in a range of $0.26 to $0.29 during the last trading day. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
In the last trading session, Idera Pharmaceuticals Inc (NASDAQ:IDRA) was up on high volume, trading at a volume of 2.07M versus its average daily volume of 1.13 million shares. At $3.50, the stock has attained market capitalization of 163.54 million. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates.
Will IDRA Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)